Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Progress in Neuro-Psychopharmacology and Biological Psychiatry is Scopus-indexed (Q2, CiteScore 6.5), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Inc..
Checked against the index lists dated .
ISSN 0278-5846Verify ISSN ↗1878-4216Verify ISSN ↗
Publisher: Elsevier Inc.
Cost to publish: About US$4,380 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 88 / 328 | 73rd | Q2 |
| Biological Psychiatry | 17 / 54 | 69th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1982–present, best quartile Q2, CiteScore 6.5.
Progress in Neuro-Psychopharmacology and Biological Psychiatry is Q2 in Pharmacology (rank 88 of 328) and Q2 in Biological Psychiatry (rank 17 of 54), by CiteScore 2025.
Progress in Neuro-Psychopharmacology and Biological Psychiatry is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.5, which places it in quartile Q2 at the 73rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.502, quartile Q1, with an H-index of 165.
The publisher lists an article processing charge of about US$4,380 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Progress in Neuro-Psychopharmacology and Biological Psychiatry is published by Elsevier Inc. Its print ISSN is 0278-5846 and its online ISSN is 1878-4216.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Progress in Neuro-Psychopharmacology and Biological Psychiatry has an h-index of 189 and a 2-year mean of 3.66 citations per paper (OpenAlex). Its Scopus CiteScore is 6.5, quartile Q2. On 2-year citations it ranks #87 of 319 Scopus journals in Pharmacology.
Progress in Neuro-Psychopharmacology and Biological Psychiatry published 332 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2026), authors are most often from China (38.9%), Brazil (5.2%) and Türkiye (4.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.2 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.